BioCrossroads has named Eli Lilly CEO, Dave Ricks, the recipient of the 2024 August M. Watanabe Life Sciences Champion of the ...

Ricks is being recognized for his contributions to Indiana’s life sciences sector and his global impact on health care ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Business leaders including Jamie Dimon, Howard Schultz, and Elon Musk weigh in on Election Day for Donald Trump, Kamala ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

“We still have a situation where there are far more patients who would like to have the treatment than what both Eli Lilly ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

They are expected to act as a catalyst in medicine, society, the economy, and even in... fuel consumption - The astounding ...

"If we're going to be a serious port, then we've got to look at bringing in containers. The container changed the world. It's ...

Like competitor Eli Lilly (LLY), Novo saw a decrease in sales of its GLP-1 diabetes drug, Ozempic. The trend continued from the previous quarter and is one that Lilly CEO David Ricks said is ...

Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to ...